SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W27403733> ?p ?o ?g. }

Showing items 1 to 100 of ±412 with 100 items per page.

W27403733 endingPage "148" @default.
W27403733 startingPage "97" @default.
W27403733 abstract "A major achievement from 500 million years of evolution is the establishment of a high secretion rate of dehydroepiandrosterone (DHEA) by the human adrenal glands coupled with the indroduction of menopause which stops secretion of estrogens by the ovary. Cessation of estrogen secretion at menopause eliminates the risks of endometrial hyperplasia and cancer which would result from non-opposed estrogen stimulation during the post-menopausal years. In fact, from the time of menopause, DHEA becomes the exclusive and tissue-specific source of sex steroids for all tissues except the uterus. Intracrinology, a term coined in 1988, describes the local formation, action and inactivation of sex steroids from the inactive sex steroid precursor DHEA. Over the past 25 years most, if not all, the genes encoding the human steroidogenic and steroid-inactivating enzymes have been cloned and sequenced and their enzymatic activity characterized. The problem with DHEA, however, is that its secretion decreases from the age of 30 years and is already decreased, on average, by 60% at time of menopause. In addition, there is a large variability in the circulating levels of DHEA with some post-menopausal women having barely detectable serum concentrations of the steroid while others have normal values. Since there is no feedback mechanism controlling DHEA secretion within ‘normal’ values, women with low DHEA will remain with such a deficit of sex steroids for their remaining lifetime. Since there is no other significant source of sex steroids after menopause, one can reasonably believe that low DHEA is involved, in association with the aging process, in a series of medical problems classically associated with post-menopause, namely osteoporosis, muscle loss, vaginal atrophy, fat accumulation, hot flashes, skin atrophy, type 2 diabetes, memory loss, cognition loss and possibly Alzheimer’s disease. A recent randomized, placebo-controlled study has shown that all the signs and symptoms of vaginal atrophy, a classical problem recognized to be due to the hormone deficiency of menopause, can be rapidly improved or corrected by local administration of DHEA without systemic exposure to estrogens. In addition, the four domains of sexual dysfucntion are improved. For the other problems of menopause, although similar large scale, randomized and placebo-controlled studies usually remain to be performed, the available evidence already strongly suggests that they could be improved, corrected or even prevented by exogenous DHEA. In men, the contribution of adrenal DHEA to the total androgen pool has been measured at 40% in 65–75-year-old men. Such data stress the necessity of blocking both the testicular and adrenal sources of androgens in order to achieve optimal benefits in prostate cancer therapy. On the other hand, the comparable decrease in serum DHEA levels observed in both sexes has less consequence in men who continue to receive a practically constant supply of testicular sex steroids during their whole life. In fact, in men, the appearance of hormone-deficiency symptoms common to women is observed at a later age and with a lower degree of severity. Consequently, DHEA replacement has shown much more easily measurable beneficial effects in women. Most importantly, despite the non-scientific and unfortunate availability of DHEA as a food supplement in the United States, a situation that discourages rigorous clinical trials on the crucial physiological and therapeutic role of DHEA, no serious adverse event related to DHEA has ever been reported in the world literature (thousands of subjects exposed) or in the monitoring of adverse events by the FDA (millions of subjects exposed), thus indicating, as expected from its known physiology, the excellent safety profile of DHEA. With today’s knowledge, one can reasonably suggest that DHEA offers the promise of a safe and efficient replacement therapy for the multiple problems related to hormone deficiency after menopause without the risks associated with estrogen-based or any other treatments." @default.
W27403733 created "2016-06-24" @default.
W27403733 creator A5065560889 @default.
W27403733 date "2010-01-01" @default.
W27403733 modified "2023-10-13" @default.
W27403733 title "DHEA, Important Source of Sex Steroids in Men and Even More in Women" @default.
W27403733 cites W100001534 @default.
W27403733 cites W1489295075 @default.
W27403733 cites W1489568108 @default.
W27403733 cites W1497860091 @default.
W27403733 cites W151453973 @default.
W27403733 cites W1525187255 @default.
W27403733 cites W1542345616 @default.
W27403733 cites W1552337395 @default.
W27403733 cites W1556633297 @default.
W27403733 cites W1574849955 @default.
W27403733 cites W1584582903 @default.
W27403733 cites W1593442063 @default.
W27403733 cites W1597656668 @default.
W27403733 cites W1602927683 @default.
W27403733 cites W1615234163 @default.
W27403733 cites W1677718874 @default.
W27403733 cites W1894618651 @default.
W27403733 cites W1930333778 @default.
W27403733 cites W1930926117 @default.
W27403733 cites W1932574503 @default.
W27403733 cites W1963947891 @default.
W27403733 cites W1964100095 @default.
W27403733 cites W1964427298 @default.
W27403733 cites W1964791011 @default.
W27403733 cites W1965154263 @default.
W27403733 cites W1965370016 @default.
W27403733 cites W1966758596 @default.
W27403733 cites W1966976625 @default.
W27403733 cites W1967206609 @default.
W27403733 cites W1967639373 @default.
W27403733 cites W1968082379 @default.
W27403733 cites W1968546477 @default.
W27403733 cites W1969373921 @default.
W27403733 cites W1969549258 @default.
W27403733 cites W1970097733 @default.
W27403733 cites W1970423626 @default.
W27403733 cites W1970499787 @default.
W27403733 cites W1975609904 @default.
W27403733 cites W1976527790 @default.
W27403733 cites W1976917710 @default.
W27403733 cites W1977417329 @default.
W27403733 cites W1977760592 @default.
W27403733 cites W1978164913 @default.
W27403733 cites W1978557500 @default.
W27403733 cites W1978953895 @default.
W27403733 cites W1980959717 @default.
W27403733 cites W1981129287 @default.
W27403733 cites W1982921037 @default.
W27403733 cites W1983415821 @default.
W27403733 cites W1983659537 @default.
W27403733 cites W1983690581 @default.
W27403733 cites W1984417600 @default.
W27403733 cites W1984770458 @default.
W27403733 cites W1985040722 @default.
W27403733 cites W1986224014 @default.
W27403733 cites W1986294723 @default.
W27403733 cites W1986442479 @default.
W27403733 cites W1987627931 @default.
W27403733 cites W1987787771 @default.
W27403733 cites W1987822553 @default.
W27403733 cites W1988860947 @default.
W27403733 cites W1989366358 @default.
W27403733 cites W1989643757 @default.
W27403733 cites W1990831152 @default.
W27403733 cites W1991903708 @default.
W27403733 cites W1992152985 @default.
W27403733 cites W1992465374 @default.
W27403733 cites W1992969830 @default.
W27403733 cites W1993675387 @default.
W27403733 cites W1995385187 @default.
W27403733 cites W1997066754 @default.
W27403733 cites W1997807118 @default.
W27403733 cites W1998235342 @default.
W27403733 cites W1998299672 @default.
W27403733 cites W1998347153 @default.
W27403733 cites W1998848456 @default.
W27403733 cites W1999078535 @default.
W27403733 cites W1999475723 @default.
W27403733 cites W1999504845 @default.
W27403733 cites W2001094153 @default.
W27403733 cites W2001532410 @default.
W27403733 cites W2002126477 @default.
W27403733 cites W2003524311 @default.
W27403733 cites W2003985632 @default.
W27403733 cites W2004527055 @default.
W27403733 cites W2004801894 @default.
W27403733 cites W2005432482 @default.
W27403733 cites W2007725108 @default.
W27403733 cites W2009066753 @default.
W27403733 cites W2011966989 @default.
W27403733 cites W2012618926 @default.
W27403733 cites W2012632792 @default.